FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2927852068> ?p ?o ?g. }

• W2927852068 endingPage "1628" @default.
• W2927852068 startingPage "1616" @default.
• W2927852068 abstract "The randomized EXCEL (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial reported a similar rate of the 3-year composite primary endpoint of death, myocardial infarction (MI), or stroke in patients with left main coronary artery disease (LMCAD) and site-assessed low or intermediate SYNTAX scores treated with percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). Whether these results are consistent in high-risk patients with diabetes, who have fared relatively better with CABG in most prior trials, is unknown. In this pre-specified subgroup analysis from the EXCEL trial, the authors sought to examine the effect of diabetes in patients with LMCAD treated with PCI versus CABG. Patients (N = 1,905) with LMCAD and site-assessed low or intermediate CAD complexity (SYNTAX scores ≤32) were randomized 1:1 to PCI with everolimus-eluting stents versus CABG, stratified by the presence of diabetes. The primary endpoint was the rate of a composite of all-cause death, stroke, or MI at 3 years. Outcomes were examined in patients with (n = 554) and without (n = 1,350) diabetes. The 3-year composite primary endpoint was significantly higher in diabetic compared with nondiabetic patients (20.0% vs. 12.9%; p < 0.001). The rate of the 3-year primary endpoint was similar after treatment with PCI and CABG in diabetic patients (20.7% vs. 19.3%, respectively; hazard ratio: 1.03; 95% confidence interval: 0.71 to 1.50; p = 0.87) and nondiabetic patients (12.9% vs. 12.9%, respectively; hazard ratio: 0.98; 95% confidence interval: 0.73 to 1.32; p = 0.89). All-cause death at 3 years occurred in 13.6% of PCI and 9.0% of CABG patients (p = 0.046), although no significant interaction was present between diabetes status and treatment for all-cause death (p = 0.22) or other endpoints, including the 3-year primary endpoint (p = 0.82) or the major secondary endpoints of death, MI, or stroke at 30 days (p = 0.61) or death, MI, stroke, or ischemia-driven revascularization at 3 years (p = 0.65). In the EXCEL trial, the relative 30-day and 3-year outcomes of PCI with everolimus-eluting stents versus CABG were consistent in diabetic and nondiabetic patients with LMCAD and site-assessed low or intermediate SYNTAX scores.(Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization [EXCEL]; NCT01205776)" @default.
• W2927852068 created "2019-04-11" @default.
• W2927852068 creator A5007010729 @default.
• W2927852068 creator A5007377189 @default.
• W2927852068 creator A5008587276 @default.
• W2927852068 creator A5009748989 @default.
• W2927852068 creator A5011188783 @default.
• W2927852068 creator A5016139987 @default.
• W2927852068 creator A5016707931 @default.
• W2927852068 creator A5023436129 @default.
• W2927852068 creator A5029019754 @default.
• W2927852068 creator A5030079078 @default.
• W2927852068 creator A5030094435 @default.
• W2927852068 creator A5043198234 @default.
• W2927852068 creator A5046037086 @default.
• W2927852068 creator A5046629853 @default.
• W2927852068 creator A5049150830 @default.
• W2927852068 creator A5060412536 @default.
• W2927852068 creator A5064708989 @default.
• W2927852068 creator A5065425489 @default.
• W2927852068 creator A5066581986 @default.
• W2927852068 creator A5067015252 @default.
• W2927852068 creator A5076880659 @default.
• W2927852068 creator A5077031363 @default.
• W2927852068 creator A5079070411 @default.
• W2927852068 creator A5082319577 @default.
• W2927852068 creator A5087872615 @default.
• W2927852068 creator A5089523236 @default.
• W2927852068 creator A5089676632 @default.
• W2927852068 date "2019-04-01" @default.
• W2927852068 modified "2023-10-16" @default.
• W2927852068 title "Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes" @default.
• W2927852068 cites W1899931514 @default.
• W2927852068 cites W1946152282 @default.
• W2927852068 cites W1966585409 @default.
• W2927852068 cites W2000046358 @default.
• W2927852068 cites W2058011848 @default.
• W2927852068 cites W2098674170 @default.
• W2927852068 cites W2098770990 @default.
• W2927852068 cites W2122104474 @default.
• W2927852068 cites W2143368051 @default.
• W2927852068 cites W2165431358 @default.
• W2927852068 cites W2167388722 @default.
• W2927852068 cites W2190454287 @default.
• W2927852068 cites W2338184685 @default.
• W2927852068 cites W2508949049 @default.
• W2927852068 cites W2512661856 @default.
• W2927852068 cites W2520210802 @default.
• W2927852068 cites W2520690001 @default.
• W2927852068 cites W2539688728 @default.
• W2927852068 cites W2544723010 @default.
• W2927852068 cites W2605396475 @default.
• W2927852068 cites W2626446274 @default.
• W2927852068 cites W2788436970 @default.
• W2927852068 cites W2789124978 @default.
• W2927852068 cites W2800245419 @default.
• W2927852068 cites W4236067666 @default.
• W2927852068 doi "https://doi.org/10.1016/j.jacc.2019.01.037" @default.
• W2927852068 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30947913" @default.
• W2927852068 hasPublicationYear "2019" @default.
• W2927852068 type Work @default.
• W2927852068 sameAs 2927852068 @default.
• W2927852068 citedByCount "57" @default.
• W2927852068 countsByYear W29278520682019 @default.
• W2927852068 countsByYear W29278520682020 @default.
• W2927852068 countsByYear W29278520682021 @default.
• W2927852068 countsByYear W29278520682022 @default.
• W2927852068 countsByYear W29278520682023 @default.
• W2927852068 crossrefType "journal-article" @default.
• W2927852068 hasAuthorship W2927852068A5007010729 @default.
• W2927852068 hasAuthorship W2927852068A5007377189 @default.
• W2927852068 hasAuthorship W2927852068A5008587276 @default.
• W2927852068 hasAuthorship W2927852068A5009748989 @default.
• W2927852068 hasAuthorship W2927852068A5011188783 @default.
• W2927852068 hasAuthorship W2927852068A5016139987 @default.
• W2927852068 hasAuthorship W2927852068A5016707931 @default.
• W2927852068 hasAuthorship W2927852068A5023436129 @default.
• W2927852068 hasAuthorship W2927852068A5029019754 @default.
• W2927852068 hasAuthorship W2927852068A5030079078 @default.
• W2927852068 hasAuthorship W2927852068A5030094435 @default.
• W2927852068 hasAuthorship W2927852068A5043198234 @default.
• W2927852068 hasAuthorship W2927852068A5046037086 @default.
• W2927852068 hasAuthorship W2927852068A5046629853 @default.
• W2927852068 hasAuthorship W2927852068A5049150830 @default.
• W2927852068 hasAuthorship W2927852068A5060412536 @default.
• W2927852068 hasAuthorship W2927852068A5064708989 @default.
• W2927852068 hasAuthorship W2927852068A5065425489 @default.
• W2927852068 hasAuthorship W2927852068A5066581986 @default.
• W2927852068 hasAuthorship W2927852068A5067015252 @default.
• W2927852068 hasAuthorship W2927852068A5076880659 @default.
• W2927852068 hasAuthorship W2927852068A5077031363 @default.
• W2927852068 hasAuthorship W2927852068A5079070411 @default.
• W2927852068 hasAuthorship W2927852068A5082319577 @default.
• W2927852068 hasAuthorship W2927852068A5087872615 @default.
• W2927852068 hasAuthorship W2927852068A5089523236 @default.
• W2927852068 hasAuthorship W2927852068A5089676632 @default.
• W2927852068 hasBestOaLocation W29278520681 @default.
• W2927852068 hasConcept C126322002 @default.

• next